U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07890168) titled 'Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients' on Oct. 18.
Brief Summary: This study aims to evaluate the combined predictive value of immune-inflammatory and metabolic biomarkers for coronary no-reflow following primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI), with the goal of improving early risk stratification and clinical decision-making.
Study Start Date: Sept. 01
Study Type: OBSERVATIONAL
Condition:
Integrated Assessment
Immune-Inflammatory
Metabolic Bioma...